Author:
Attar Sabah,Price Angie,Hovinga Collin,Stewart Breanne,Lacaze-Masmonteil Thierry,Bonifazi Fedele,Turner Mark A.,Fernandes Ricardo M.
Abstract
Abstract
Background
Despite global efforts to improve paediatric clinical trials, significant delays continue in paediatric drug approvals. Collaboration between research networks is needed to address these delays. This paper is a first step to promote interoperability between paediatric networks from different jurisdictions by comparing drivers for, and content of, metrics about clinical trial conduct.
Methods
Three paediatric networks, Institute for Advanced Clinical Trials for Children, the Maternal Infant Child and Youth Research Network and conect4children, have each developed metrics to address delays and create efficiencies. We identified the methodology by which each network identified metrics, described the metrics of each network, and mapped consistency to come to consensus about core metrics that networks could share.
Results
Metric selection was driven by site quality improvement in one network (11 metrics), by network performance in one network (13 metrics), and by both in one network (five metrics). The domains of metrics were research capacity/capability, site identification/feasibility, trial start-up, and recruitment/enrolment. The network driven by site quality improvement did not have indicators for capacity/capability or identification/feasibility. Fifteen metrics for trial start up and conduct were identified. Metrics related to site approvals were found in all three networks. The themes for metrics can inform the development of ‘shared’ metrics.
Conclusion
We found disparity in drivers, methodology and metrics. Tackling this disparity will result in a unified approach to addressing delays in paediatric drug approvals. Collaborative work to define inter-operable metrics globally is outlined.
Funder
Innovative Medicines Initiative
Canadian Institute for Health Research
Food and Drug Administration
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Pica N, Bourgeois F. Discontinuation and nonpublication of randomized clinical trials conducted in children. Pediatrics. 2016. https://doi.org/10.1542/peds.2016-0223.
2. Brewster R, et al. Early discontinuation, results reporting, and publication of pediatric clinical trials. Pediatrics. 2022. https://doi.org/10.1542/peds.2021-052557.
3. IOM (Institute of Medicine). Envisioning a transformed clinical trials enterprise in the United States: establishing an agenda for 2020: workshop summary. Washington: The National Academies Press; 2012.
4. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation. Envisioning a Transformed Clinical Trials Enterprise for 2030: Proceedings of a Workshop. Shore C, Gee AW, Wizemann T, editors. Washington (DC): National Academies Press (US); 2021
5. Turner MA, et al. European research networks to facilitate drug research in children. Br J Clin Pharmacol. 2022;88(10):4258–66.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献